Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04
The average one-year price target for Immix Biopharma (NASDAQCM:IMMX) has been revised to $25.04 / share. This is an increase of 10.16% from the prior estimate of $22.73 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation orinvestment adviceby Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $17.57 to a high of $31.50 / share, widening from the prior range of $15.15 to $28.35. The current target range width is $13.93, which is a +5.50% change from the prior width of $13.20. The average price target represents an increase of 144.78% from the latest reported closing price of $10.23 / share as of October 1, 2026. The median target also increased to $26.01 from $23.46, representing an absolute median change of $2.55.
This update marks the 6 consecutive target revision direction increase for Immix Biopharma. Looking at the target history, the mean target was $21.13 on August 4, 2026, rose to $21.71 on August 28, 2026, reached $22.73 on September 15, 2026, and is currently $25.04 as of October 2, 2026. This current mean target of $25.04 represents the observed twelve-month high mean, while the observed twelve-month low mean was $8.16 on December 6, 2025. The target change since the 90-day baseline date of July 1, 2026, is +18.79%.
In terms of analyst ratings, Needham maintained a Buy grade on September 29, 2026, and Mizuho maintained an Outperform grade on September 15, 2026. The recommendation trend for the period of September 1, 2026, shows 3 strong buy, 9 buy, and 1 hold recommendations, which is unchanged from the August 1, 2026, period.
As context for the company's recent market activity, the stock price has experienced a decline. The price change over one week was -12.56% from a baseline close of $11.70 on September 24, 2026. Over one month, the price change was -26.98% from a baseline close of $14.01 on September 1, 2026. In its latest earnings report on August 7, 2026, Immix Biopharma reported an actual EPS of -0.18 compared to an estimated EPS of -0.1792, with both actual and estimated revenue reported at $0.00.
Immix Biopharma operates in the Biotechnology sub-industry within the Health Care sector. Out of 24 covered companies in this sub-industry, 6 have raised targets, 7 have lowered, and 11 remain unchanged. The sub-industry median revision percent is 0.00%, with a median implied change percent of +81.91%.
Among its peers, Allarity Therapeutics saw a positive target revision, while Prothena and Citius Oncology remained unchanged.
| Company | Target revision | Implied change |
|---|---|---|
| Prothena | 0.00% | +155.60% |
| Citius Oncology | 0.00% | +316.33% |
| Allarity Therapeutics | +7.32% | +978.85% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.